Ashkan Mortezavi
Universitätsspital Basel · University Hospital, Basel, Switzerland
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ashkan Mortezavi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:25 UTC. Open this list on ClinicalTrials.gov
- N/ANCT05294627 · Validation of the Stockholm3 Test for Detection of Prostate Cancer in the Swiss PopulationUniversity Hospital, Basel, Switzerland · completed · Prostate Cancer, Localized Carcinoma · principal investigator
- Ph3NCT03903835 · ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerKarolinska Institutet · recruiting · Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:25 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:25 UTC. The ranking covers the 200 most relevant of 8 PubMed records, and a shared surname and initials can bring in a namesake. All 8 on PubMed
- 55 citationsRCR 2.6
- 45 citationsRCR 1.4
- 68Ga-PSMA-11 PET/MR Detects Local Recurrence Occult on mpMRI in Prostate Cancer Patients After HIFU.J Nucl Med · 201944 citationsRCR 1.9
- Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial.Nat Med · 202428 citationsRCR 2.9
- 18 citationsRCR 1.2
- Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform Trial.Eur Urol Oncol · 202510 citationsRCR 2.2
- Anxiety and Health-related Quality of Life in Men with Prostate Cancer Undergoing Focal Therapy: A Prospective Single-arm Phase 2 Trial.Eur Urol Focus · 20251 citationsRCR 0.7
- 0 citationsRCR 0.0